POPULAR SECTIONS

TREATMENT REGIMENS DRUG INFO MEDICAL CALCULATORS PUBLISHERS ALLIANCE VIDEOS CME

Head and Neck Cancer Trial Completes Enrollment

Share this article:

(ChemotherapyAdvisor) – A treatment for head and neck cancer is now on its way into Phase 3 clinical trials. Oncolytics Biotech Inc. announced today that it has completed enrollment in the first stage of its Phase 3 clinical trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018).

The comparative assessment of intravenous administration of REOLYSIN with the chemotherapy combination of paclitaxel and carboplatin versus the chemotherapy alone will take place in patients with metastatic or recurrent squamous cell carcinoma of the head and neck, or squamous cell cancer of the nasopharynx, who have progressed while (or after) receiving prior platinum-based chemotherapy.

In this randomized, two-arm, double-blind, multicenter, two-stage, adaptive trial, all patients will receive treatment every three weeks (21-day cycles) with paclitaxel and carboplatin, and will also receive, on a blinded basis, either intravenous placebo or intravenous REOLYSIN. All dosing takes place in the first five days of each cycle, with all patients receiving standard intravenous doses of paclitaxel and carboplatin on day one only, and on days one through five, either intravenous placebo or intravenous REOLYSIN.

The trial must meet the primary endpoint of overall survival (OS). The trial has just completed enrollment for the first, or non-adaptive, stage, which is designed to enroll 80 patients. The next stage will be adaptive and is designed to enroll between 100 and 400 patients.

The multicenter trial will be conducted at more than 80 centers in 12 countries in North America and Europe, including the U.S.

Press Release

Share this article:

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.
close

Next Article in Head and Neck Cancer

Sign Up for Free e-newsletters

Community Poll

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Head and Neck Cancer

Oral Human Papillomavirus (HPV) Infection Risk Increased by Three Daily Cigarettes

Oral Human Papillomavirus (HPV) Infection Risk Increased by ...

Cigarette smokers are more likely to be positive for human papillomavirus (HPV)-16 compared with non-smokers.

In Addition to Breast, Ovarian Cancers, BRCA Mutations May Increase Risk of Salivary Gland Cancers

In Addition to Breast, Ovarian Cancers, BRCA Mutations ...

Mutations with the genes breast cancer 1 and 2, early onset may increase a person's risk for developing salivary gland cancer.

Alpelisib Plus Cetuximab may be Effective for Patients with Cetuximab-Resistant Head and Neck Cancer

Alpelisib Plus Cetuximab may be Effective for Patients ...

BYL719, an effective treatment in combination with cetuximab in patients with cetuximab-resistant head and neck cancer.